Home Careers Contact

Price: 3.15

Change: 0.00

Day High: 3.20
Day Low: 3.10
Volume: 548,047

4:00 PM ET | Sep 25, 2017
Delayed 20 min., by eSignal.



Shareholder Tools

Press Releases

Company News
View Summary Cempra Appoints Dr. David Zaccardelli as Acting Chief Executive Officer, Promotes Chief Commercial Officer David Moore to President
Dec 12, 2016
PDF 19.9 KB Add to Briefcase
View Summary Toyama Chemical (a Subsidiary of FUJIFILM Holdings Corporation) Begins Phase 3 Studies in Japan With Cempra's Solithromycin
Dec 5, 2016
PDF 17.2 KB Add to Briefcase
View Summary Cempra to Present at Two Upcoming Investor Conferences
Nov 9, 2016
PDF 16.8 KB Add to Briefcase
View Summary FDA Advisory Committee Votes That Efficacy Results of Cempra's Solithromycin Outweigh Risks for Community-Acquired Bacterial Pneumonia
Nov 4, 2016
PDF 19.5 KB Add to Briefcase
View Summary Cempra Stock Trading Halted Today; FDA Advisory Committee to Discuss Solithromycin
Nov 4, 2016
PDF 16.8 KB Add to Briefcase
View Summary Cempra Receives $10 Million Milestone Payment From Toyama Chemical (a Subsidiary of FUJIFILM Holdings Corporation) as Solithromycin Progresses to Phase 3 Studies in Japan
Nov 1, 2016
PDF 17.1 KB Add to Briefcase
View Summary Cempra Reports Third Quarter 2016 Financial Results and Provides Corporate Update
Oct 27, 2016
PDF 32.9 KB Add to Briefcase
View Summary Cempra to Report Third Quarter 2016 Financial Results
Oct 25, 2016
PDF 14.9 KB Add to Briefcase
View Summary Cempra Presents Analysis Showing Rates of Failure for Existing CABP Antibiotics From Claims Database at Academy of Managed Care Pharmacy Meeting
Oct 4, 2016
PDF 22.2 KB Add to Briefcase
View Summary Cempra Announces Anti-NASH Effects of Solithromycin: Interim Results From Phase 2 Study
Sep 29, 2016
PDF 72.1 KB Add to Briefcase
Showing 21-30 of 238 Page: 1 2 3 4 5 6 7 ... 24  Previous 10 | Next 10
Add to Briefcase = add release to Briefcase